Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Qinhao Wang
The Chimeric Ubiquitin Ligase SH2-U-box Inhibits the Growth of Imatinib-Sensitive and Resistant CML by Targeting the Native and T315i-Mutant BCR-ABL
Scientific Reports
Multidisciplinary
Related publications
Targeting the SH2-Kinase Interface in BCR-Abl Inhibits Leukemogenesis
Cell
Biochemistry
Genetics
Molecular Biology
Simultaneous Targeting of Aurora Kinases and BCR-Abl Kinase by the Small Molecule Inhibitor PHA-739358 Is Effective Against Imatinib-Resistant BCR-ABL Mutations Including T315I
Blood
Biochemistry
Immunology
Cell Biology
Hematology
Coexistence of AML1/RUNX1 and BCR-ABL Point Mutations in an Imatinib-Resistant Form of CML
Leukemia
Cancer Research
Oncology
Anesthesiology
Pain Medicine
Hematology
NPB001-05 Inhibits BCR-Abl Kinase Leading to Apoptosis of Imatinib-Resistant Cells
Frontiers in Bioscience - Elite
Immunology
Molecular Biology
Biochemistry
Microbiology
Medicine
Genetics
A Type-Ii Kinase Inhibitor Capable of Inhibiting the T315I “Gatekeeper” Mutant of BCR-Abl
Journal of Medicinal Chemistry
Drug Discovery
Molecular Medicine
SRC Family Kinases Phosphorylate the BCR-Abl SH3-SH2 Region and Modulate BCR-Abl Transforming Activity
Journal of Biological Chemistry
Biochemistry
Cell Biology
Molecular Biology
Broad Spectrum Alkynyl Inhibitors of T315I BCR-Abl
Bioorganic and Medicinal Chemistry Letters
Organic Chemistry
Molecular Medicine
Molecular Biology
Biochemistry
Clinical Biochemistry
Pharmaceutical Science
Drug Discovery
Multidomain Targeting of BCR-Abl by Disruption of Oligomerization and Tyrosine Kinase Inhibition: Toward Eradication of CML
Molecular Pharmaceutics
Drug Discovery
Molecular Medicine
Pharmaceutical Science
Discovery and Characterization of a Novel Potent Type II Native and Mutant BCR-ABL Inhibitor (CHMFL-074) for Chronic Myeloid Leukemia (CML)
Oncotarget
Oncology
